A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. [electronic resource]
Producer: 20040528Description: 755-63 p. digitalISSN:- 0929-1903
- Adenoviridae -- genetics
- Adjuvants, Immunologic
- Aged
- Cells, Cultured
- Dendritic Cells -- immunology
- Disease Susceptibility
- Genetic Therapy -- adverse effects
- Humans
- Immunotherapy -- adverse effects
- Inflammation -- immunology
- Interferon-gamma -- immunology
- Interleukin-2 -- adverse effects
- Interleukin-4 -- immunology
- Male
- Middle Aged
- Prostate-Specific Antigen -- analysis
- Prostatic Neoplasms -- genetics
- T-Lymphocytes -- immunology
- Treatment Outcome
- Vaccination
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.